Why the study?
Does evening administration of indobufen reduce morning platelet aggregation in patients with ischaemic heart disease?
Does evening administration of indobufen reduce morning platelet aggregation in patients with ischaemic heart disease?
Evening administration of indobufen effectively inhibits the morning peak in platelet aggregation in patients with ischemic heart disease.
Answers are grounded in this paper and cite their sources.
May inform chronotherapy with indobufen in IHD; leaves open whether it improves clinical outcomes, needing RCTs.
Platelets are involved in the progression of coronary atherosclerosis as well as in the development of the acute precipitating event. Recently, it has been shown that normal subjects present increased platelet aggregation between 6.00 a.m. and 9.00 a.m.; epidemiological studies have shown a higher incidence of myocardial infarction between these times. This study evaluated, by an impedence method using whole blood, platelet aggregation induced by ADP (3 microM) and collagen (2 microM/ml). Measurements were made at 6.00 a.m., 9.00 a.m. and 12.00 noon, the day before and the day after evening administration of 200 mg indobufen, a platelet aggregation inhibitor, in 12 patients with ischaemic heart disease. Patients showed a significant increase of platelet aggregation between 6.00 a.m. and 9.00 a.m. which was inhibited by the prior evening administration of indobufen.
No takes yet. Share an insight, caveat, or question.
Craveri et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: